Results 11 to 20 of about 1,096 (177)

Varespladib Inhibits the Phospholipase A₂ and Coagulopathic Activities of Venom Components from Hemotoxic Snakes [PDF]

Biomedicines, 2020
Phospholipase A2 (PLA2) enzymes are important toxins found in many snake venoms, and they can exhibit a variety of toxic activities including causing hemolysis and/or anticoagulation.
Chunfang Xie, Laura-Oana Albulescu, Kristina B. M. Still, Julien Slagboom, Yumei Zhao, Zhengjin Jiang, Govert W. Somsen, Freek J. Vonk, Nicholas R. Casewell, Jeroen Kool   +9 more
doaj   +13 more sources

Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib [PDF]

Toxins, 2021
Bites from elapid snakes typically result in neurotoxic symptoms in snakebite victims. Neurotoxins are, therefore, often the focus of research relating to understanding the pathogenesis of elapid bites.
Taline D. Kazandjian, Arif Arrahman, Kristina B. M. Still, Govert W. Somsen, Freek J. Vonk, Nicholas R. Casewell, Mark C. Wilkinson, Jeroen Kool   +7 more
doaj   +12 more sources

A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib [PDF]

Toxins, 2022
Envenomation by elapid snakes primarily results in neurotoxic symptoms and, consequently, are the primary focus of therapeutic research concerning such venoms. However, mounting evidence suggests these venoms can additionally cause coagulopathic symptoms,
Arif Arrahman, Taline D. Kazandjian, Kristina B. M. Still, Julien Slagboom, Govert W. Somsen, Freek J. Vonk, Nicholas R. Casewell, Jeroen Kool   +7 more
doaj   +12 more sources

Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation [PDF]

Molecules, 2018
Phospholipase A2s (PLA2) is a major component of snake venom with diverse pathologic toxicities and, therefore, a potential target for antivenom therapy. Varespladib was initially designed as an inhibitor of mammal PLA2s, and was recently repurposed to a
Yiding Wang, Jing Zhang, Denghong Zhang, Huixiang Xiao, Shengwei Xiong, Chunhong Huang   +5 more
doaj   +6 more sources

Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms [PDF]

Toxins, 2020
The phospholipase A2 (PLA2) inhibitor Varespladib (LY315920) and its orally bioavailable prodrug, methyl-Varespladib (LY333013) inhibit PLA2 activity of a wide variety of snake venoms.
José María Gutiérrez, Matthew R. Lewin, David. J. Williams, Bruno Lomonte   +3 more
doaj   +8 more sources

PLA₂ Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky’s Viper Vipera berus nikolskii [PDF]

Toxins, 2020
Although envenoming by a small East European species of viper is rarely severe, and only exceptionally fatal, lack of specific antivenom stocks in a few areas within this region and possible severe side effects of antivenom application leave most bites ...
Oleksandr Zinenko, Igor Tovstukha, Yevgen Korniyenko   +2 more
doaj   +6 more sources

Dermonecrosis caused by a spitting cobra snakebite results from toxin potentiation and is prevented by the repurposed drug varespladib. [PDF]

Proc Natl Acad Sci U S A
Significance Spitting cobra venoms cause extensive local tissue damage surrounding the site of a snakebite. This damage cannot be effectively prevented with current antivenom treatments, and patients are often left with life-changing wounds.
Bartlett KE, Hall SR, Rasmussen SA, Crittenden E, Dawson CA, Albulescu LO, Laprade W, Harrison RA, Saviola AJ, Modahl CM, Jenkins TP, Wilkinson MC, Gutiérrez JM, Casewell NR.   +13 more
europepmc   +12 more sources

A-002 (Varespladib), a phospholipase A₂ inhibitor, reduces atherosclerosis in guinea pigs [PDF]

BMC Cardiovascular Disorders, 2009
Background The association of elevated serum levels of secretory phospholipase A2 (sPLA2) in patients with cardiovascular disease and their presence in atherosclerotic lesions suggest the participation of sPLA2 enzymes in this disease.
Fraser Heather, Puglisi Michael, Vaishnav Ushma, Leite Jose O, Trias Joaquim, Fernandez Maria   +5 more
doaj   +10 more sources

Correction: Wang et al. Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Molecules 2018, 23, 391 [PDF]

Molecules, 2022
The authors would like to correct an error in the original publication [...]
Yiding Wang, Jing Zhang, Denghong Zhang, Huixiang Xiao, Shengwei Xiong, Chunhong Huang   +5 more
doaj   +4 more sources

Dermonecrosis caused by spitting cobra snakebite results from toxin potentiation and is prevented by the repurposed drug varespladib [PDF]

Proceedings of the National Academy of Sciences, 2023
AbstractSnakebite envenoming is a neglected tropical disease that causes substantial mortality and morbidity globally. The venom of African spitting cobras often causes permanent injury via tissue-destructive dermonecrosis at the bite site, which is ineffectively treated by current antivenoms.
Bartlett KE, Hall SR, Rasmussen SA, Crittenden E, Dawson CA, Albulescu L, Laprade W, Harrison RA, Saviola AJ, Modahl CM, Jenkins TP, Wilkinson MC, Gutiérrez JM, Casewell NR.   +13 more
europepmc   +7 more sources